Literature DB >> 11937576

Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis.

Zivana Tezak1, Eric P Hoffman, Jennica L Lutz, Tamara O Fedczyna, Dietrich Stephan, Eric G Bremer, Irina Krasnoselska-Riz, Ajit Kumar, Lauren M Pachman.   

Abstract

Juvenile dermatomyositis (JDM), the most common pediatric inflammatory myopathy, is a systemic vasculopathy affecting young children. Epidemiology studies documenting an antecedent illness in the 3 mo before the first definite symptom (rash and/or weakness) of JDM are supported by immunologic data that suggest that the disease pathophysiology is Ag driven. The purpose of this study was to compare the gene expression profiles in muscle biopsies of four untreated DQA1*0501(+) JDM children with profiles from children with a known necrotizing myopathy (Duchenne muscular dystrophy), as well as an in vitro antiviral model (NF90), and healthy pediatric controls. Nearly half (47%) of the dysregulated genes in JDM were associated with the immune response. In particular, increased expression of IFN-alphabeta-inducible genes 6-16, myxovirus resistance protein p78, latent cytosolic transcription factor, LMP2, and TAP1 was observed. This profile is consistent with an IFN-alphabeta transcription cascade seen in the in vitro viral resistance model. The IFN-alphabeta-inducible profile was superimposed on transcription profiles reflective of myofiber necrosis and regeneration shared with Duchenne muscular dystrophy. Expressed genes were confirmed by quantitative real-time PCR (6-16), immunofluorescence (thrombospondin 4), and immunolocalization (IFN-gamma, p21). We hypothesize that these data support a model of Ag (?viral) induction of an apparent autoimmune disease based on dynamic interaction between the muscle, vascular, and immune systems in the genetically susceptible (DQA1*0501(+)) child.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11937576     DOI: 10.4049/jimmunol.168.8.4154

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  62 in total

1.  Coexpression analysis of human genes across many microarray data sets.

Authors:  Homin K Lee; Amy K Hsu; Jon Sajdak; Jie Qin; Paul Pavlidis
Journal:  Genome Res       Date:  2004-06       Impact factor: 9.043

Review 2.  Update on the assessment of children with juvenile idiopathic inflammatory myopathy.

Authors:  Adam M Huber
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

3.  Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells.

Authors:  Sheela Shrestha; Barry Wershil; John F Sarwark; Timothy B Niewold; Teresa Philipp; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2010-09

Review 4.  Clinical manifestations and pathogenesis of hydroxyapatite crystal deposition in juvenile dermatomyositis.

Authors:  Lauren M Pachman; Adele L Boskey
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.592

5.  An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity.

Authors:  Emily C Baechler; Jason W Bauer; Catherine A Slattery; Ward A Ortmann; Karl J Espe; Jill Novitzke; Steven R Ytterberg; Peter K Gregersen; Timothy W Behrens; Ann M Reed
Journal:  Mol Med       Date:  2007 Jan-Feb       Impact factor: 6.354

Review 6.  Dendritic cells and cytokines in human inflammatory and autoimmune diseases.

Authors:  Patrick Blanco; A Karolina Palucka; Virginia Pascual; Jacques Banchereau
Journal:  Cytokine Growth Factor Rev       Date:  2008-02       Impact factor: 7.638

Review 7.  Advances in the immunobiology and treatment of inflammatory myopathies.

Authors:  Marinos C Dalakas
Journal:  Curr Rheumatol Rep       Date:  2007-08       Impact factor: 4.592

Review 8.  Dermatomyositis.

Authors:  M S Krathen; D Fiorentino; V P Werth
Journal:  Curr Dir Autoimmun       Date:  2008

9.  The inflammatory milieu in idiopathic inflammatory myositis.

Authors:  Ann M Reed; Floranne Ernste
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

10.  Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis.

Authors:  Kelly A Rouster-Stevens; Gabrielle A Morgan; Deli Wang; Lauren M Pachman
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-10       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.